BioMimetic Therapeutics Inc. today reported positive results from a 52-week clinical trial of its Augment Bone Graft product. In short, the study reinforces data from previous 24-week trial, showing BioMimetic's product is as effective as, and in some cases superior to the current standard of care for foot and ankle fusion surgery.
“The 52 week data from the Augment North American pivotal clinical trial demonstrate that patients treated with Augment have just as good an outcome after one year, and a favorable safety profile, compared to patients treated with autograft," said BioMimetic CEO Sam Lynch in a statement. "And, the patients treated with Augment have the added benefits of not having the additional pain and risk of a procedure to harvest the autograft from another bone in their body."
In addition, that bone harvesting costs between $1,100 and $2,400, according to BioMimetic.
The company's stock (Ticker: BMTI) was rising on the news Wednesday morning.